Scinovex
review Open AccessTop 1% cited

Guidelines for the management of adult lower respiratory tract infections

European Respiratory Journal · 2005 · Vol. 26(6) · pp. 1138–1180
Mark WoodheadF. BlasiS. EwigG. HuchonM. LevenA. OrtqvistT. SchabergA. TorresG. van der HeijdenT. J. M. Verheij

Abstract

No risk factors for P. aeruginosa (see table 12) Nonantipseudomonal cephalosporin III+macrolide # or Nonantipseudomonal cephalosporin III+(moxifloxacin or levofloxacin) Risk factors for P. aeruginosa (see table 12) Anti-pseudomonal cephalosporin " or Acylureidopenicillin/b-lactamase inhibitor or Carbapenem + ciprofloxacin P. aeruginosa: Pseudomonas aeruginosa.# : new macrolides preferred to erythromycin

Respiratory and Cough-Related ResearchChronic Obstructive Pulmonary Disease (COPD) ResearchPediatric health and respiratory diseasesGuidelineMedicineIntensive care medicineRespiratory tract infectionsPneumoniaCommunity-acquired pneumoniaTask forceSpecialtyPublic healthFamily medicine

MeSH terms

AdultAmbulatory CareAnti-Bacterial AgentsDrug Therapy, CombinationFemaleHospitalizationHumansMaleMiddle AgedPneumoniaPrognosisRespiratory Tract InfectionsSeverity of Illness IndexSurvival RateTreatment Outcome
Citations
891
FWCI
40.11
field-weighted impact
References
389
Percentile
100%
vs. same field & year
Citations per year
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.